Eli Lilly Pulls 'Ineffective' Sepsis Drug Xigris

Law360, New York (October 25, 2011, 5:06 PM EDT) -- Eli Lilly & Co. will withdraw its sepsis-treatment drug Xigris from the market after clinical trials found no benefit to using it, the pharmaceutical giant announced Tuesday.

The company voluntarily agreed to discontinue the drug after a study of about 1,700 patients, designed to more clearly identify the treatment's target population and confirm the drug's risks and benefits, found no statistically significant reduction of mortality in patients.

No new safety risks were identified, although the drug has carried a severe-bleeding warning on its label since its...
To view the full article, register now.